Addex director resets option, share strikes to $0.032

Addex Therapeutics director repriced options and deferred strike obligations to $0.032 per share without changing his share or option counts.

Rhea-AI Filing Summary

Addex Therapeutics Ltd. (ADXN) director Isaac Manke reported repricing equity incentives on September 2, 2026. An option covering 50,000 common shares and deferred strike obligations on 219,561 previously acquired shares were reset to an exercise or strike price of $0.032 per share, with all other terms unchanged and no net change in the number of shares or options held. These actions are described as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act and were not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Manke Isaac

Role Director

Type	Security	Shares	Price	Value
Disposition	Stock-option (Right to Buy) F3, F2	50,000	$0.00	$0.00
Grant/Award	Stock-option (Right to Buy) F3, F2	50,000	$0.00	$0.00
Disposition	Common Stock F1	219,561	$0.00	$0.00
Grant/Award	Common Stock F1	219,561	$0.00	$0.00

Holdings After Transaction: Stock-option (Right to Buy) — 50,000 contracts (Direct); Common Stock — 219,561 shares (Direct)

Footnotes (3)

1. F1. Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
2. F2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.
3. F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

Key Figures

Option shares repriced: 50,000 shares Shares under deferred strike plan: 219,561 shares New exercise or strike price: $0.032 per share +5 more

8 metrics

Option shares repriced 50,000 shares Option covering common stock repriced on September 2, 2026

Shares under deferred strike plan 219,561 shares Common shares on SIX Swiss Exchange subject to deferred strike obligations repriced on September 2, 2026

New exercise or strike price $0.032 per share Applies to the option and deferred strike obligations after September 2, 2026 decision

Prior option exercise price $0.062 per share Original exercise price for the 50,000-share option before repricing

Initial strike price 2022 tranche $0.16 per share Applied to 128,238 shares acquired on October 26, 2022 before reset to $0.032

Initial strike price 2023 tranche $0.053 per share Applied to 91,323 shares acquired on November 27, 2023 before reset to $0.032

FX rate used for strike prices $1.2296 per CHF 1.00 Conversion from Swiss francs to U.S. dollars as of September 2, 2026

Option expiration date January 7, 2034 Expiration of the repriced 50,000-share option

Key Terms

deferred strike price payment plan, Rule 16b-6(d), Rule 16b-3, exercise price

4 terms

deferred strike price payment plan financial

"acquired on October 26, 2022 under the deferred strike price payment plan"

Rule 16b-6(d) regulatory

"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"

Rule 16b-3 regulatory

"Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

exercise price financial

"the exercise price of options was repriced to $0.032"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What did Addex Therapeutics (ADXN) director Isaac Manke report on this Form 4?

He reported repricing an option for 50,000 common shares and deferred strike obligations on 219,561 previously acquired shares as of September 2, 2026, while leaving the number of shares and options unchanged.

What new strike or exercise price was set in the Addex Therapeutics (ADXN) Form 4?

The exercise or strike price for the affected option and deferred strike obligations was set to $0.032 per share on September 2, 2026, replacing higher prior strike prices while keeping all other terms the same.

Were any Addex Therapeutics (ADXN) shares bought or sold by the director in this filing?

No. The filing describes repricing of an option and deferred strike obligations on already acquired shares, with no net change in the number of common shares or options held by the director.

What prior exercises and strike prices are referenced in the Addex Therapeutics (ADXN) Form 4 footnotes?

The 219,561 shares were acquired earlier: 128,238 shares on October 26, 2022 at an initial strike of $0.16 per share and 91,323 shares on November 27, 2023 at an initial strike of $0.053 per share, later reset to $0.032.

Was a Rule 10b5-1 trading plan involved in the Addex Therapeutics (ADXN) transactions?

No. The Form 4 indicates that no Rule 10b5-1 trading plan applied, and the footnotes instead describe the transactions as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.

What foreign exchange rate was used for the Addex Therapeutics (ADXN) strike price conversions?

Strike and exercise prices are reported in U.S. dollars using an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026, according to the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:04 PM Accepted by SEC EDGAR 09/04/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manke Isaac

(Last) (First) (Middle)

405 DORADO BEACH EAST

(Street)

DORADO PUERTO RICO 00646

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol
[[ADXN]]

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		D(1)		219,561	D	$0(1)	0	D
Common Stock	09/02/2026		A(1)		219,561	A	$0(1)	219,561	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-option (Right to Buy)	$0.062(3)	09/02/2026		D(2)			50,000	01/08/2024	01/07/2034	Common Stock	50,000	$0	0	D
Stock-option (Right to Buy)	$0.032(3)	09/02/2026		A(2)		50,000		01/08/2024	01/07/2034	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable. The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

2. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

	/s/ Lenaic Nathanael Teyssedou by power of attorney	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)